Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review
| Autor: | Jesse X. Yang, Robert W. Yeh |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Coronary Artery Disease 030204 cardiovascular system & hematology Coronary Angiography Prosthesis Design Coronary artery disease Angina 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine medicine Humans Bare metal Zotarolimus cardiovascular diseases 030212 general & internal medicine Stent thrombosis Cardiac catheterization Sirolimus business.industry Stent Percutaneous coronary intervention Drug-Eluting Stents equipment and supplies medicine.disease Surgery Treatment Outcome surgical procedures operative Molecular Medicine Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Future Cardiology. 14:251-267 |
| ISSN: | 1744-8298 1479-6678 |
| DOI: | 10.2217/fca-2017-0091 |
| Popis: | Drug-eluting stents revolutionized the treatment of coronary artery disease with vastly improved outcomes compared with bare metal stents. As stent technology has evolved, a wide variety of antiproliferative drugs have been developed to prevent stent restenosis and stent thrombosis. The Resolute stent system (Medtronic, CA, USA) elutes zotarolimus from a multipolymer blend to prevent early and late stent-related complications. The Resolute stents have evolved from the initial Resolute stent, to the Resolute Integrity™ and most recently, the Resolute Onyx™. These stents have been studied across a wide range of patients and coronary syndromes. They compare similarly in performance to their contemporary second generation stents. We present a review of the major trials involving these zotarolimus-eluting stents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|